← Patent-cliff monitor small molecule RETEVMO SELPERCATINIB
Loss of exclusivity April 2039 latest FDA-listed patent expiry
Company ELI LILLY AND CO
Drug detail Brand name RETEVMO Active ingredient SELPERCATINIB Strength 80MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2024 Marketing status RX
Listed patents Patent Expires Type 12138250*PED April 2039 — 12138250 October 2038 use U-3949 10172851*PED April 2038 — 10137124*PED April 2038 — 10112942*PED April 2038 — 10137124 October 2037 use U-3951 10112942 October 2037 substance, product 10172851 October 2037 use U-3951
Regulatory exclusivity Code Expires PED November 2031 ODE* May 2031 PED March 2030 ODE* September 2029 PED March 2028 PED November 2027 M-312 September 2027 M-311 September 2027 ODE* May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.